SurModics Inc. (SRDX) CEO Gary R. Maharaj Sells 5,000 Shares of Stock
SurModics Inc. (NASDAQ:SRDX) CEO Gary R. Maharaj sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, October 3rd. The stock was sold at an average price of $29.55, for a total transaction of $147,750.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Shares of SurModics Inc. (NASDAQ:SRDX) opened at 30.42 on Thursday. SurModics Inc. has a 12-month low of $17.45 and a 12-month high of $30.75. The company’s 50-day moving average is $29.02 and its 200-day moving average is $24.44. The company has a market capitalization of $396.83 million, a price-to-earnings ratio of 45.47 and a beta of 0.97.
SurModics (NASDAQ:SRDX) last released its earnings results on Thursday, July 28th. The company reported $0.37 EPS for the quarter, topping analysts’ consensus estimates of $0.12 by $0.25. SurModics had a net margin of 14.45% and a return on equity of 17.11%. The company had revenue of $19.97 million for the quarter, compared to analysts’ expectations of $16.31 million. During the same quarter last year, the business earned $0.30 EPS. The firm’s revenue was up 25.6% compared to the same quarter last year. Analysts predict that SurModics Inc. will post $1.04 EPS for the current year.
Large investors have recently added to or reduced their stakes in the company. Picton Mahoney Asset Management purchased a new stake in SurModics during the first quarter worth approximately $101,000. Bank of Montreal Can bought a new stake in shares of SurModics during the second quarter worth about $190,000. Capstone Asset Management Co. bought a new stake in shares of SurModics during the second quarter worth about $203,000. Public Sector Pension Investment Board bought a new stake in shares of SurModics during the second quarter worth about $209,000. Finally, TFS Capital LLC bought a new stake in shares of SurModics during the second quarter worth about $224,000. Institutional investors own 86.42% of the company’s stock.
Separately, Zacks Investment Research lowered shares of SurModics from a “buy” rating to a “hold” rating in a report on Tuesday, July 5th.
SurModics Company Profile
SurModics, Inc is a provider of surface modification and in vitro diagnostic technologies to the healthcare industry. The Company operates through two segments: Medical Device and In Vitro Diagnostics. The Company is focused on to transform its medical device business from being a provider of coating technologies to offering whole product solutions to medical device customers.
Receive News & Ratings for SurModics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SurModics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.